Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA's Drug Promotion Advisory Reviews Taking Longer

Executive Summary

FDA is having trouble meeting its internal goal of 45-day reviews for core launch materials due to complex issues that have required medical review division consultations, Office of Prescription Drug Promotion Director Abrams says.


Related Content

Off-Label Communication: Pfizer Highlights Burdens Of FDA Policy
Remoxy's Woes Stoke Criticism Of FDA's Review Of Abuse-Deterrent Opioids
FDA's Decline In Promotion Enforcement Highlighted By Celator Booth Letter
Off-Label Debate Between FDA, Industry To Formally Begin After Election
FDA's Rx Promotion Citation Drought Continued In 2015





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts